Researchers reported the link between aging, cancer, and epigenomic changes.
Controversial Alzheimer’s Drug Abandoned
Biogen will discontinue its controversial Alzheimer’s disease drug aducanumab (Aduhelm), the company announced Wednesday. The drugmaker will stop developing and selling aducanumab, an anti-amyloid monoclonal